US › Healthcare

Annovis Bio Inc (ANVS)

US · Healthcare · Biotechnology

$1.10+5.77%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-14.8M

EPS

$-0.40

EPS estimate

$-0.44

EPS came in at -0.40 against a street estimate of -0.44 — a beat of 9.1%.

Key statistics

Market cap

$44.4M

Forward P/E

0.0

P/B

25.18

Book value

$-0.10

EPS (TTM)

$-1.63

52-week high

$5.50

52-week low

$1.04

50-day MA

$1.70

200-day MA

$2.38

Beta

1.24

Analyst view

Analysts rate Annovis Bio Inc a buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $10.50.

Shareholding

Insiders

6.71%

Institutions

27.91%

Largest institutional holders

Fund	Stake
Empery Asset Management, LP	5.64%
Marshall Wace Asset Management Ltd	2.79%
Vanguard Capital Management, LLC	2.05%
Two Sigma Investments LLC	1.47%
Renaissance Technologies Corp	0.82%
Geode Capital Management, LLC	0.58%
Susquehanna International Group, LLP	0.51%
Northern Trust Corp	0.33%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Annovis Bio Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.